OUR DEVELOPMENT PORTFOLIO

Updated January 2020

Cardiovascular diseases
Diabetes
Cancer
Immune-
Inflammatory diseases
Neuropsychiatric diseases

Phase 1

Haematological malignancies/Solid tumors

Mcl1 inhibitor

Haematological malignancies

Bcl2 inhibitor

Haematological malignancies

UCART 19

Cancer

Anti PD1xAnti TIM3

Cancer

Anti PD1xAnti LAG3

Haematological malignancies

Cart 19

Sjögren disease/UC

Anti IL7R

Phase 2

Cancer, 1st line

mPaCa / Liposomal Irinotecan

Lung cancer, 2nd line

Liposomal Irinotecan

Venous leg ulcers

Ischemic stroke

TAFIa inhibitor

Osteoarthritis

ADAMTS-5 inhibitor

Phase 3

Chronic heart failure

Omecamtiv mecarbil

Colorectal cancer, 1st line

Trifluridine/Tipiracil

Type 2 diabetes

Exenatide implant

Autism

Bumetanide